TY - JOUR AU - Goldman, J. M. AU - Melo, J. V. PY - 2003 DA - 2003// TI - Chronic myeloid leukemia: advances in biology and new approaches to treatment JO - N Engl J Med VL - 349 UR - https://doi.org/10.1056/NEJMra020777 DO - 10.1056/NEJMra020777 ID - Goldman2003 ER - TY - JOUR AU - Saglio, G. AU - Guerrasio, A. AU - Rosso, C. AU - Zaccaria, A. AU - Tassinari, A. AU - Serra, A. PY - 1990 DA - 1990// TI - New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia JO - Blood VL - 76 ID - Saglio1990 ER - TY - JOUR AU - Wilson, G. A. AU - Vandenberghe, E. A. AU - Pollitt, R. C. AU - Rees, D. C. AU - Goodeve, A. C. AU - Peake, I. R. PY - 2000 DA - 2000// TI - Are aberrant BCR-ABL transcripts more common than previously thought? JO - Br J Haematol VL - 111 UR - https://doi.org/10.1046/j.1365-2141.2000.02471.x DO - 10.1046/j.1365-2141.2000.02471.x ID - Wilson2000 ER - TY - JOUR AU - Crampe, M. AU - Garry, J. AU - Langabeer, S. E. AU - Murphy, P. T. PY - 2016 DA - 2016// TI - Sustained molecular response with nilotinib in imatinib-intolerant chronic myeloid leukaemia with an e19a2 BCR-ABL1 fusion JO - Hematol Oncol Stem Cell Ther VL - 9 UR - https://doi.org/10.1016/j.hemonc.2016.05.007 DO - 10.1016/j.hemonc.2016.05.007 ID - Crampe2016 ER - TY - JOUR AU - How, G. F. AU - Tan, L. T. AU - Lim, L. C. PY - 1998 DA - 1998// TI - Chronic myeloid leukemia with e19a2 (c3a2) BCR/ABL fusion junction: is it truly a benign disease? JO - Leukemia VL - 12 UR - https://doi.org/10.1038/sj.leu.2401055 DO - 10.1038/sj.leu.2401055 ID - How1998 ER - TY - JOUR AU - Andrikovics, H. AU - Nahajevszky, S. AU - Szilvási, A. AU - Bors, A. AU - Adám, E. AU - Kozma, A. PY - 2007 DA - 2007// TI - First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts JO - Hematol Oncol VL - 25 UR - https://doi.org/10.1002/hon.822 DO - 10.1002/hon.822 ID - Andrikovics2007 ER - TY - JOUR AU - Qin, Y. Z. AU - Jiang, Q. AU - Jiang, H. AU - Lai, Y. Y. AU - Shi, H. X. AU - Chen, W. M. PY - 2018 DA - 2018// TI - Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single Centre JO - Br J Haematol VL - 182 UR - https://doi.org/10.1111/bjh.15453 DO - 10.1111/bjh.15453 ID - Qin2018 ER - TY - JOUR AU - Baccarani, M. AU - Deininger, M. W. AU - Rosti, G. AU - Hochhaus, A. AU - Soverini, S. AU - Apperley, J. F. PY - 2013 DA - 2013// TI - European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 JO - Blood VL - 122 UR - https://doi.org/10.1182/blood-2013-05-501569 DO - 10.1182/blood-2013-05-501569 ID - Baccarani2013 ER - TY - JOUR AU - Gabert, J. AU - Beillard, E. AU - van der Velden, V. H. AU - Bi, W. AU - Grimwade, D. AU - Pallisgaard, N. PY - 2003 DA - 2003// TI - Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against Cancer program JO - Leukemia VL - 17 UR - https://doi.org/10.1038/sj.leu.2403135 DO - 10.1038/sj.leu.2403135 ID - Gabert2003 ER - TY - JOUR AU - Branford, S. AU - Rudzki, Z. AU - Walsh, S. AU - Parkinson, I. AU - Grigg, A. AU - Szer, J. PY - 2003 DA - 2003// TI - Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis JO - Blood VL - 102 UR - https://doi.org/10.1182/blood-2002-09-2896 DO - 10.1182/blood-2002-09-2896 ID - Branford2003 ER - TY - JOUR AU - Jabbour, E. AU - Kantarjian, H. AU - Jones, D. AU - Talpaz, M. AU - Bekele, N. AU - O'Brien, S. PY - 2006 DA - 2006// TI - Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate JO - Leukemia VL - 20 UR - https://doi.org/10.1038/sj.leu.2404318 DO - 10.1038/sj.leu.2404318 ID - Jabbour2006 ER - TY - JOUR AU - Jabbour, E. AU - Jones, D. AU - Kantarjian, H. M. AU - O'Brien, S. AU - Tam, C. AU - Koller, C. PY - 2009 DA - 2009// TI - Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations JO - Blood VL - 114 UR - https://doi.org/10.1182/blood-2009-01-197715 DO - 10.1182/blood-2009-01-197715 ID - Jabbour2009 ER - TY - JOUR AU - Hughes, T. P. AU - Saglio, G. AU - Quintás-Cardama, A. AU - Mauro, M. J. AU - Kim, D. W. AU - Lipton, J. H. PY - 2015 DA - 2015// TI - BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase JO - Leukemia VL - 29 UR - https://doi.org/10.1038/leu.2015.168 DO - 10.1038/leu.2015.168 ID - Hughes2015 ER - TY - JOUR AU - Naqvi, K. AU - Cortes, J. E. AU - Luthra, R. AU - O'Brien, S. AU - Wierda, W. AU - Borthakur, G. PY - 2018 DA - 2018// TI - Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations JO - Int J Hematol VL - 107 UR - https://doi.org/10.1007/s12185-018-2422-6 DO - 10.1007/s12185-018-2422-6 ID - Naqvi2018 ER - TY - JOUR AU - Redaelli, S. AU - Mologni, L. AU - Rostagno, R. AU - Piazza, R. AU - Magistroni, V. AU - Ceccon, M. PY - 2012 DA - 2012// TI - Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors JO - Am J Hematol VL - 87 UR - https://doi.org/10.1002/ajh.23338 DO - 10.1002/ajh.23338 ID - Redaelli2012 ER - TY - JOUR AU - Griswold, I. J. AU - MacPartlin, M. AU - Bumm, T. AU - Goss, V. L. AU - O'Hare, T. AU - Lee, K. A. PY - 2006 DA - 2006// TI - Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib JO - Mol Cell Biol VL - 26 UR - https://doi.org/10.1128/MCB.02202-05 DO - 10.1128/MCB.02202-05 ID - Griswold2006 ER - TY - JOUR AU - Gruber, F. X. AU - Ernst, T. AU - Porkka, K. AU - Engh, R. A. AU - Mikkola, I. AU - Maier, J. PY - 2012 DA - 2012// TI - Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients JO - Leukemia VL - 26 UR - https://doi.org/10.1038/leu.2011.187 DO - 10.1038/leu.2011.187 ID - Gruber2012 ER - TY - JOUR AU - Soverini, S. AU - De Benedittis, C. AU - Machova Polakova, K. AU - Brouckova, A. AU - Horner, D. AU - Iacono, M. PY - 2013 DA - 2013// TI - Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain JO - Blood VL - 122 UR - https://doi.org/10.1182/blood-2013-03-487728 DO - 10.1182/blood-2013-03-487728 ID - Soverini2013 ER - TY - BOOK PY - 2017 DA - 2017// TI - ARIAD Pharma Ltd PB - Leatherhead CY - UK ID - ref19 ER - TY - JOUR AU - Ferri, C. A. AU - Bianchini, M. AU - Bengió, R. M. AU - Moiraghi, E. B. AU - Gonzalez, M. S. AU - Noriega, M. F. PY - 2015 DA - 2015// TI - Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation JO - Eur J Haematol VL - 94 UR - https://doi.org/10.1111/ejh.12358 DO - 10.1111/ejh.12358 ID - Ferri2015 ER -